Biotech - Rare Diseases
•207 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (207)
| Company | Market Cap | Price |
|---|---|---|
|
CELZ
Creative Medical Technology Holdings, Inc.
FDA Orphan Drug Designation for brittle Type 1 Diabetes indicates a rare-disease focus.
|
$6.04M |
$2.30
+3.60%
|
|
XAIR
Beyond Air, Inc.
BA-102 in NeuroNOS has Orphan Drug Designation, aligning with rare-disease biotech development.
|
$6.01M |
$1.23
-3.91%
|
|
BCLI
Brainstorm Cell Therapeutics Inc.
ALS is a rare neurodegenerative disease, aligning with the Rare Diseases biotech segment and supporting NurOwn's positioning as a therapy for a rare condition.
|
$3.91M |
$0.60
|
|
QNRX
Quoin Pharmaceuticals, Ltd.
Lead program targets a rare disease (Netherton Syndrome) and is developed by a biotech focused on rare diseases.
|
$3.05M |
$10.76
-43.10%
|
|
JAGX
Jaguar Health, Inc.
The company targets rare intestinal diseases (MVID, SBS-IF) with crofelemer programs, fitting the Rare Diseases biotech segment.
|
$2.35M |
$1.05
-4.09%
|
|
NLSP
NLS Pharmaceutics AG
Historically focused on rare CNS disorders, aligning NLSP with Rare Diseases biotechnologies.
|
$358802 |
$0.79
-78.02%
|
|
EMMA
Emmaus Life Sciences, Inc.
The company operates in the rare diseases therapeutic area, centered on Endari for sickle cell disease.
|
$18251 |
$0.01
|
Showing page 3 of 3 (207 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
